Global Information
회사소개 | 문의

니코틴 중독 : 파이프라인 리뷰

Nicotine Addiction - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 245978
페이지 정보 영문 66 Pages
가격
US $ 2,000 ₩ 2,296,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,592,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,888,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


니코틴 중독 : 파이프라인 리뷰 Nicotine Addiction - Pipeline Review, H2 2018
발행일 : 2018년 08월 페이지 정보 : 영문 66 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

니코틴 중독이란 담배 안에 들어 있는 니코틴이라는 성분에 의해 급성이나 만성의 신체 증상이 발생하는 것입니다. 연령, 우울증, 정신분열증, 외상 후 스트레스 장애(PTSD), 알콜 등의 요인에 의해 발병하며, 섭취 중단시에는 손떨림, 발한, 신경과민, 심장박동 증가 등의 금단 증상이 나타나는 경우도 있습니다. 니코틴 대체요법 등으로 치료합니다.

니코틴 중독(Nicotine Addiction) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

니코틴 중독 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

니코틴 중독 : 기업에서 개발중인 치료제

니코틴 중독 : 대학/연구기관에서 연구중인 치료제

니코틴 중독 : 파이프라인 제품 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

니코틴 중독 : 기업에서 개발중인 제품

니코틴 중독 : 대학/연구기관에서 연구중인 제품

니코틴 중독 치료제 개발에 참여하고 있는 기업

  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Embera NeuroTherapeutics, Inc.
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Omeros Corporation
  • RTI International

니코틴 중독 : 치료제 평가

  • 단일요법(Monotherapy) 제품별
  • 병용 제품
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

니코틴 중독 : 최근의 파이프라인 동향

니코틴 중독 : 개발 휴지 상태인 프로젝트

니코틴 중독 : 개발이 중지된 제품

니코틴 중독 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 16.07.22

List of Tables

  • Number of Products under Development for Nicotine Addiction, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H2 2018
  • Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd, H2 2018
  • Nicotine Addiction - Pipeline by CV Sciences Inc, H2 2018
  • Nicotine Addiction - Pipeline by Heptares Therapeutics Ltd, H2 2018
  • Nicotine Addiction - Pipeline by Indivior Plc, H2 2018
  • Nicotine Addiction - Pipeline by Omeros Corp, H2 2018
  • Nicotine Addiction - Dormant Projects, H2 2018
  • Nicotine Addiction - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Nicotine Addiction, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H2 2018, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape.

Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 16 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nicotine Addiction - Overview
    • Nicotine Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Nicotine Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nicotine Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Chronos Therapeutics Ltd
    • CV Sciences Inc
    • Heptares Therapeutics Ltd
    • Indivior Plc
    • Omeros Corp
  • Nicotine Addiction - Drug Profiles
    • (cannabidiol + nicotine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 18-MC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-4113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-6527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-3009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-4X3256 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EORA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Noribogaine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • psilocybin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBP-0069330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nicotine Addiction - Dormant Projects
  • Nicotine Addiction - Discontinued Products
  • Nicotine Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Jul 20, 2017: CV Sciences Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure
      • Jul 11, 2017: CV Sciences Appoints Dr. Amy M. McCord as Director of Drug Development
      • Jun 19, 2017: CV Sciences Announces Commencement of IND preparation immediately following Pre-IND Meeting With FDA
      • May 02, 2017: CV Sciences Announces Pre-IND Meeting Date with FDA
      • May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development
      • Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
      • Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
      • Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine
      • May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research